Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human safety, tolerability, PK/PD study of TAK-925 in healthy volunteers and narcolepsy type 1 patients
jRCT2080223700Phase 1Completed
- Sponsor
- Takeda
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of danavorexton in narcolepsy type 1 (NT1) (4 arms), sponsored by Takeda. Primary endpoints: Safety and tolerability of TAK-925, Pharmacokinetics of TAK-925 and 1 more. Started Nov 2017; status: completed.
02
Drugs
danavorexton
03
Conditions
narcolepsy type 1 (NT1)
Beyond the preview
Go deeper on jRCT2080223700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223700.